Mutations in BRCA2 and taxane resistance in prostate cancer

Mutations in BRCA1 or BRCA2 define a subset of prostate cancer patients. Herein, we address the question whether BRCA1/2 mutations have a predictive impact on chemotherapy with docetaxel, a widely used drug in patients with metastatic castration resistant prostate cancer (mCRPC). Fifty-three men tre...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Sci Rep
Asıl Yazarlar: Nientiedt, Cathleen, Heller, Martina, Endris, Volker, Volckmar, Anna-Lena, Zschäbitz, Stefanie, Tapia-Laliena, María A., Duensing, Anette, Jäger, Dirk, Schirmacher, Peter, Sültmann, Holger, Stenzinger, Albrecht, Hohenfellner, Markus, Grüllich, Carsten, Duensing, Stefan
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group UK 2017
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5496866/
https://ncbi.nlm.nih.gov/pubmed/28676659
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-017-04897-x
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller